Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC3FOW)

Drug Name

Imsidolimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Generalized pustular psoriasis	EA90.40	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting IL-1 receptor-like 2 (IL1RL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Spesolimab	DM9FZYT	Psoriasis vulgaris	EA90	Approved	[3]
Nemvaleukin alfa	DMOAZHY	Ovarian cancer	2C73	Phase 3	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT05366855) A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis. U.S.National Institutes of Health.
2	Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023 Jul 17;189(2):161-169.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.